With all of the pipeline success we're seeing from the Big Biotech stocks lately, Big Pharma's more hit-and-miss recent drug development track record hasn't gone unnoticed.

Today, Pfizer announced that it was halting a phase 3 trial for inotuzumab ozogamicin in aggressive non-Hodgkin's lymphoma, as it wasn't showing any survival benefit over the control group. It was a surprise cancellation, and there had been a lot of enthusiasm around this drug, which targeted an antigen found in more than 90% of b-cell malignancies.

In this video, health-care analyst David Williamson discusses what this drug failure means for Pfizer, its competitors, and its investors.

David Williamson owns shares of Pfizer. Follow David on Twitter: @MotleyDavid.

The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.